JP7169645B2 - 生体組織中の異種抗原を不活性化する方法 - Google Patents
生体組織中の異種抗原を不活性化する方法 Download PDFInfo
- Publication number
- JP7169645B2 JP7169645B2 JP2018546756A JP2018546756A JP7169645B2 JP 7169645 B2 JP7169645 B2 JP 7169645B2 JP 2018546756 A JP2018546756 A JP 2018546756A JP 2018546756 A JP2018546756 A JP 2018546756A JP 7169645 B2 JP7169645 B2 JP 7169645B2
- Authority
- JP
- Japan
- Prior art keywords
- bioprosthetic
- tissue
- substitute
- treated
- inactivating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
- A61L27/3687—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment characterised by the use of chemical agents in the treatment, e.g. specific enzymes, detergents, capping agents, crosslinkers, anticalcification agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
- A61L27/3625—Vascular tissue, e.g. heart valves
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0205—Chemical aspects
- A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
- A01N1/0226—Physiologically active agents, i.e. substances affecting physiological processes of cells and tissue to be preserved, e.g. anti-oxidants or nutrients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/20—Materials or treatment for tissue regeneration for reconstruction of the heart, e.g. heart valves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/40—Preparation and treatment of biological tissue for implantation, e.g. decellularisation, cross-linking
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Botany (AREA)
- Dermatology (AREA)
- Medicinal Chemistry (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- General Chemical & Material Sciences (AREA)
- Environmental Sciences (AREA)
- Dentistry (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Physiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Materials For Medical Uses (AREA)
- Medicines Containing Plant Substances (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Prostheses (AREA)
Description
-前記組織からの異種エピトープの少なくとも一部を不活性化するために、フェノール化合物、ポリフェノール化合物、又はそれらの誘導体に基づく溶液を用意する工程と;
-制御された条件下、フェノール/ポリフェノールに基づく種々の溶液中で処理すべき試料をインキュベートする工程と;
-処理された組織を一連の洗浄に供する工程と
を伴うことを特徴とする方法によって達成される。
-最も適切な用量のフェノール化合物、ポリフェノール化合物、又はそれの誘導体が溶解される緩衝液を含有する1又は複数の容器;
-緩衝液と組み合わせるための粉末形態の前記用量のフェノール化合物、ポリフェノール化合物、又はそれらの誘導体を含有する1又は複数の容器;
-洗浄緩衝液を含有する1又は複数の容器;
-処置を施すタイミング及び様式の説明を含む取扱説明書
を含むことを特徴とするキットに関する。
「フェノール化合物」の用語は、少なくともその一部が、1又は複数のヒドロキシル官能基に結合した芳香族核(ベンゼン環)の存在によって特徴付けられる分子を指す。上記の化合物には、排他的ではない例として、単純フェノール(単一のベンゼン環を有し、ヒドロキシル基のみを置換基として含む分子、例えばフェノール及びヒドロキノン)、フェノールアルデヒド(フェノール基とアルデヒド基の両方を含む、例えばバニリンアルデヒド(aldeide vanillica))、フェノール酸(例えば桂皮酸)、フェニルアミン(弱酸性基および強塩基性基を含む両性分子、例えばフェニルアラニン)、フェノール化合物(フェノール環が別のベンゼン環又はヒドロキシル/ラクトン/ケトン官能基を有する他の複素環化合物に結合している、例えばクマリン及びキサントン)、フラボノイド(酸素化複素環を構成する3つの炭素原子を有する鎖によって連結された2個のベンゼン環で構成される、例えばカテキン、フラボノン、フラボン、カルコン、フラバノノール、フラバノール、ロイコアントシアニジン、アントシアニジン)、フェニルプロパノイド(3個の炭素原子を有する脂肪族側鎖を有する芳香環の存在を特徴とする、例えばヒドロキシ桂皮酸)、並びにタンニンが含まれる。本発明において、「フェノール」及び「ポリフェノール」の用語は同じ意味を有することができ、一緒に使用することも、あるいは設定される狙いのために互いに取って代わることもできる。
-前記組織からの異種エピトープの少なくとも一部を不活性化するために、フェノール化合物、ポリフェノール化合物ま、又はそれらの誘導体に基づく溶液を用意する工程と;
-制御された条件下、フェノール/ポリフェノールに基づく種々の溶液中で処理すべき試料をインキュベートする工程と;
-処理された組織を一連の洗浄に供する工程と
を含む。
-「HANCK」として図中に示されるHancock II(商標)ブタ心臓弁(モデルT510、Medtronic Inc.,ミネアポリス、米国);
-「FREE」として図中に示されるFreestyle(登録商標)大動脈根心臓弁(モデル995、Medtronic Inc.,ミネアポリス、米国);
-「SAV」として図中に示されるCarpentier-Edwards S.A.V.(モデル6650、Edwards Lifesciences LCC、カリフォルニア、米国);
-「PERI」として図中に示されるCarpentier-Edwards Perimount Plus(モデル6900P、Edwards Lifesciences LCC、カリフォルニア、米国);
-「CC」として図中に示されるCardioCel心血管パッチ(モデルC0404、Admedus Regen Pty Ltd、パース、オーストラリア)。
-方法T1:[1:20]の比の5mM~50mMの濃度(本発明では、20mM濃度を採用した)のコーヒー酸/チロシナーゼ1ml当たり600±50Uのリン酸ナトリウムの緩衝液;
-方法T2:0.2±0.1MのNaOH中5mM~50mMの濃度(本発明では、20mM濃度を採用した)のコーヒー酸;
-方法T3:リン酸ナトリウム緩衝液中0.1M~1.5Mの濃度(本発明では、1M濃度を採用した)のタンニン酸;
-方法T4:0.2±0.1MのNaOH中0.3mM~10mMの濃度(本発明では、6mM濃度を採用した)のヒドロキシチロソール。
-最も適切な用量のフェノール化合物、ポリフェノール化合物、又はそれらの誘導体が溶解される緩衝液を含有する1又は複数の容器;
-緩衝液と組み合わせるための粉末形態の前記用量のフェノール化合物、ポリフェノール化合物、又はそれらの誘導体を含有する1又は複数の容器;
-洗浄緩衝液を含有する1又は複数の容器;
-処置を施すタイミング及び様式の説明を含む取扱説明書
を含む。
- Nkomo VT et al. Burden of valvular heart diseases: a population- based study. Lancet 2006;368: 1005-1011.
- Zeng LY et al. A prompt method to quantitative assay of alpha-Gal on pig cell surface without injury. Sichuan Da XUe Xue Bao Yi Xue Ban. 2005;36(3):419-421.
- Galili U et al. A sensitive assay for measuring alpha Gal epitope expression on cells by a monoclonal anti-Gal antibody. Transplantation 1998;65: 1129-1132.
- Chen RH et al. alpha-Gal and beta-Gal are preferentially expressed on porcine cardiac microvascular endothelium. Transplant Proc 2000;32:877-878.
- Feng W et al. Distribution of the Alpha-Gal epitope on adult porcine bone tissue. Transplant. Proceed. 2006;38:2247-2251.
- Galili U. The alpha Gal epitope and the anti-Gal antibody in xenotransplantation and in cancer immunotherapy. Immun Cell Biol 2005;83 :674-686.
- Konakci KZ et al. Alpha-Gal on bioprostheses: xenograft immune response in cardiac surgery. Eur J Clin Invest 2005;35(1): 17-23.
- Park CS et al. Anti alpha-gal immune response following porcine bioprosthesis implantation in children. J Heart Valve Dis 2010; 19(1): 124- 30.
- Lila N et al. Gal knockout pig pericardium: new source of material for heart valve bioprostheses. J Heart Lung Transplant 2 010;29(5):538-43.
- Naso F et al. First quantitative assay of alpha- Gal in soft tissues: presence and distribution of the epitope before and after cell removal from xenogeneic heart valves. Acta Biomater 2011 ;7(4): 1728-1734.
- Naso F et al. First quantification of alpha-Gal epitope in current glutaraldehyde-fixed heart valve bioprostheses. Xenotransplantation 2013;20(4):252-261.
Claims (6)
- 生体組織中、並びに/又はヒト若しくは獣医学臨床用途のために既に調製及び意図された生体補綴代替物中の異種抗原を不活性化する方法であって、以下の工程:
-前記生体組織及び/又は生体補綴代替物からのα-Gal抗原の少なくとも一部を不活性化するために、コーヒー酸を含有する溶液を用意する工程と;
-制御された条件下、前記溶液中で、処理すべき前記生体組織及び/又は前記生体補綴代替物をインキュベートする工程と;
-前記処理された生体組織及び/又は生体補綴代替物を一連の洗浄に供する工程と;
を伴うことを特徴とする、方法。 - 前記生体組織が天然、または天然および固定、または固定結合組織によって構成されることを特徴とする、請求項1に記載の方法。
- 前記生体組織が異種性又は同種性であることを特徴とする、請求項1又は2に記載の方法。
- 前記制御された条件が、少なくとも40±2℃の温度での処理を含むことを特徴とする、請求項1~3のいずれか1項に記載の方法。
- ヒト又は獣医学臨床分野で使用するための、生体補綴代替物及び/又は生体補綴代替物の部分を製造する方法であって、以下の工程:
-生体組織からのα-Gal抗原の少なくとも一部を不活性化するために、コーヒー酸を含有する溶液を用意する工程と;
-制御された条件下、前記溶液中で、処理すべき前記生体補綴代替物及び/又は前記生体補綴代替物の部分をインキュベートする工程と;
-前記処理された生体補綴代替物及び/又は生体補綴代替物の部分を一連の洗浄に供する工程と;
を伴い、
前記生体補綴代替物及び/又は生体補綴代替物の部分は、不活性型のα-Gal抗原の少なくとも一部を有することを特徴とする、方法。 - 請求項1~4のいずれか1項に記載の生体組織中の異種抗原を不活性化する方法を実施するためのキットであって、少なくとも
-最も適切な用量のコーヒー酸が溶解される緩衝液を含有する1又は複数の容器;
-緩衝液と組み合わせるための粉末形態の前記用量のコーヒー酸を含有する1又は複数の容器;
-洗浄緩衝液を含有する1又は複数の容器;
-処置を施すタイミング及び様式の説明を含む取扱説明書
を含むことを特徴とする、キット。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ITUB2015A006019A ITUB20156019A1 (it) | 2015-11-30 | 2015-11-30 | Metodo per l'inattivazione di xenoantigeni in tessuti biologici |
IT102015000078236 | 2015-11-30 | ||
PCT/EP2016/078898 WO2017093147A1 (en) | 2015-11-30 | 2016-11-25 | Method for inactivating xenoantigens in biological tissues |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2019503821A JP2019503821A (ja) | 2019-02-14 |
JP7169645B2 true JP7169645B2 (ja) | 2022-11-11 |
Family
ID=55485194
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018546756A Active JP7169645B2 (ja) | 2015-11-30 | 2016-11-25 | 生体組織中の異種抗原を不活性化する方法 |
Country Status (19)
Country | Link |
---|---|
US (1) | US20180353647A1 (ja) |
EP (1) | EP3383446B1 (ja) |
JP (1) | JP7169645B2 (ja) |
KR (1) | KR20180090816A (ja) |
CN (1) | CN108367098B (ja) |
AU (1) | AU2016363536B2 (ja) |
BR (1) | BR112018011021B1 (ja) |
CA (1) | CA3006234A1 (ja) |
CU (1) | CU24631B1 (ja) |
DK (1) | DK3383446T3 (ja) |
ES (1) | ES2881603T3 (ja) |
IL (1) | IL259591B (ja) |
IT (1) | ITUB20156019A1 (ja) |
MX (1) | MX2018006577A (ja) |
PL (1) | PL3383446T3 (ja) |
RS (1) | RS62100B1 (ja) |
RU (1) | RU2754197C2 (ja) |
WO (1) | WO2017093147A1 (ja) |
ZA (1) | ZA201803786B (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT201600115523A1 (it) * | 2016-11-16 | 2018-05-16 | Biocompatibility Innovation Srl | Metodo per l'inattivazione ed il controllo di avvenuta inattivazione di xenoantigeni in alimenti di origine animale, particolarmente per latte e derivati, e in alimenti di origine vegetale, particolarmente per succedanei di latte a base di soia e/o riso |
EP3972659A1 (en) | 2019-05-22 | 2022-03-30 | Biocompatibility Innovation Srl | Method for preventing the formation of calcified deposits and for inactivating xenoantigens in biological matrices |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003520825A (ja) | 2000-01-25 | 2003-07-08 | ボード・オブ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ネブラスカ | 抗ドナー免疫へ抵抗する、移植前に順応された臓器 |
WO2004047620A3 (en) | 2002-11-26 | 2005-02-24 | Univ Clemson | Fixation method for bioprostheses |
WO2007133479A2 (en) | 2006-05-10 | 2007-11-22 | Cook Incorporated | Delivery of elastin-stabilizing compound within a body lumen |
JP2014516695A (ja) | 2011-05-18 | 2014-07-17 | バトリックス・メディカル・インコーポレイテッド | 血管安定化用被覆バルーン |
US20150087611A1 (en) | 2013-09-24 | 2015-03-26 | Clemson University | Multi-step Connective Tissue Stabilization Method and Stabilized Tissue Formed Thereby |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1734814T3 (en) * | 2004-03-17 | 2015-04-07 | Revivicor Inc | Tissue DERIVED FROM ANIMALS IS MISSING ANY EXPRESSION OF FUNCTIONAL ALPHA-1,3 galactosyltransferase |
EP1951067B1 (en) * | 2005-11-10 | 2017-07-26 | Hill's Pet Nutrition, Inc. | Compositions and methods for improving skin health and pelage quality |
CN101366979B (zh) * | 2008-09-03 | 2012-08-29 | 陕西瑞盛生物科技有限公司 | 一种组织补片及其制备方法 |
FR2947456B1 (fr) * | 2009-07-06 | 2012-03-09 | Univ Bordeaux 1 | Procede d'inactivation d'au moins un agent pathogene dans un echantillon de plasma sanguin humain |
IL210162A0 (en) * | 2010-12-21 | 2011-03-31 | Omrix Biopharmaceuticals | Viral inactivated platelet extract, use and preparation thereof |
RU2495928C2 (ru) * | 2012-01-30 | 2013-10-20 | Сергей Юрьевич Лешков | Средство для стимуляции синтеза белков теплового шока hsp 70 в клетках человека и животных; косметическое средство для стимуляции репаративных процессов; косметическое средство для снижения побочных эффектов агрессивных косметологических процедур; биологически активная добавка; пищевой продукт; способ снижения побочных эффектов агрессивных косметологических процедур |
ITPD20120029A1 (it) | 2012-02-09 | 2013-08-10 | Alessandro Gandaglia | Metodo per la rilevazione di uno xenoantigene in tessuti fissati usati come sostituti bioprotesici |
-
2015
- 2015-11-30 IT ITUB2015A006019A patent/ITUB20156019A1/it unknown
-
2016
- 2016-11-25 ES ES16801773T patent/ES2881603T3/es active Active
- 2016-11-25 EP EP16801773.9A patent/EP3383446B1/en active Active
- 2016-11-25 RS RS20210866A patent/RS62100B1/sr unknown
- 2016-11-25 PL PL16801773T patent/PL3383446T3/pl unknown
- 2016-11-25 JP JP2018546756A patent/JP7169645B2/ja active Active
- 2016-11-25 MX MX2018006577A patent/MX2018006577A/es unknown
- 2016-11-25 US US15/779,953 patent/US20180353647A1/en active Pending
- 2016-11-25 BR BR112018011021-3A patent/BR112018011021B1/pt active IP Right Grant
- 2016-11-25 AU AU2016363536A patent/AU2016363536B2/en active Active
- 2016-11-25 DK DK16801773.9T patent/DK3383446T3/da active
- 2016-11-25 RU RU2018123621A patent/RU2754197C2/ru active
- 2016-11-25 CA CA3006234A patent/CA3006234A1/en active Pending
- 2016-11-25 CU CU2018000048A patent/CU24631B1/es unknown
- 2016-11-25 KR KR1020187016622A patent/KR20180090816A/ko not_active Application Discontinuation
- 2016-11-25 CN CN201680069993.5A patent/CN108367098B/zh active Active
- 2016-11-25 WO PCT/EP2016/078898 patent/WO2017093147A1/en active Application Filing
-
2018
- 2018-05-24 IL IL259591A patent/IL259591B/en unknown
- 2018-06-07 ZA ZA2018/03786A patent/ZA201803786B/en unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003520825A (ja) | 2000-01-25 | 2003-07-08 | ボード・オブ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ネブラスカ | 抗ドナー免疫へ抵抗する、移植前に順応された臓器 |
WO2004047620A3 (en) | 2002-11-26 | 2005-02-24 | Univ Clemson | Fixation method for bioprostheses |
WO2007133479A2 (en) | 2006-05-10 | 2007-11-22 | Cook Incorporated | Delivery of elastin-stabilizing compound within a body lumen |
JP2014516695A (ja) | 2011-05-18 | 2014-07-17 | バトリックス・メディカル・インコーポレイテッド | 血管安定化用被覆バルーン |
US20150087611A1 (en) | 2013-09-24 | 2015-03-26 | Clemson University | Multi-step Connective Tissue Stabilization Method and Stabilized Tissue Formed Thereby |
Non-Patent Citations (4)
Title |
---|
Journal of Heart Valve Desease,2015年01月,Vol.24, No.1,pp.92-100 |
New Food Industry, Vol.27, No.2(1985), p.53-60 |
Xenotransplantation,2013年,Vol.20,pp.252-261 |
日腎会誌,2005年,Vol.47, No.2,pp.83-93 |
Also Published As
Publication number | Publication date |
---|---|
CU20180048A7 (es) | 2018-11-06 |
BR112018011021A2 (pt) | 2018-11-21 |
AU2016363536B2 (en) | 2021-04-01 |
JP2019503821A (ja) | 2019-02-14 |
AU2016363536A1 (en) | 2018-06-28 |
US20180353647A1 (en) | 2018-12-13 |
ITUB20156019A1 (it) | 2017-05-30 |
CN108367098A (zh) | 2018-08-03 |
ZA201803786B (en) | 2019-02-27 |
CU24631B1 (es) | 2022-12-12 |
IL259591A (en) | 2018-07-31 |
ES2881603T3 (es) | 2021-11-30 |
RS62100B1 (sr) | 2021-08-31 |
CA3006234A1 (en) | 2017-06-08 |
MX2018006577A (es) | 2018-09-05 |
BR112018011021B1 (pt) | 2021-12-07 |
WO2017093147A1 (en) | 2017-06-08 |
DK3383446T3 (da) | 2021-07-26 |
EP3383446B1 (en) | 2021-04-28 |
PL3383446T3 (pl) | 2021-11-02 |
EP3383446A1 (en) | 2018-10-10 |
IL259591B (en) | 2022-04-01 |
RU2018123621A (ru) | 2020-01-09 |
RU2018123621A3 (ja) | 2020-04-10 |
KR20180090816A (ko) | 2018-08-13 |
CN108367098B (zh) | 2021-06-11 |
RU2754197C2 (ru) | 2021-08-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2185447C (en) | Treated tissue for implantation and preparation methods | |
CN103705980B (zh) | 加帽生物假体组织以减少钙化 | |
Ramm et al. | Decellularization combined with enzymatic removal of N‐linked glycans and residual DNA reduces inflammatory response and improves performance of porcine xenogeneic pulmonary heart valves in an ovine in vivo model | |
US11951078B2 (en) | Method for preventing the formation of calcified deposits and for inactivating xenoantigens in biological matrices | |
Naso et al. | Alpha-Gal inactivated heart valve bioprostheses exhibit an anti-calcification propensity similar to knockout tissues | |
McGregor et al. | Physical equivalency of wild type and galactose α 1, 3 galactose free porcine pericardium; a new source material for bioprosthetic heart valves | |
JP2013526889A (ja) | 石灰化物質を減少させた体内に移植するためのバイオプロテーゼを得るための方法。 | |
Connolly et al. | Triglycidyl amine crosslinking combined with ethanol inhibits bioprosthetic heart valve calcification | |
AU2014341866B2 (en) | Methods of removing alpha-galactose | |
JP7169645B2 (ja) | 生体組織中の異種抗原を不活性化する方法 | |
EP2626701B1 (en) | Method for detecting a xenoantigen in fixed tissues used as bioprosthetic replacements | |
Schoen et al. | Bioprosthetic heart valve calcification: clinicopathologic correlations, mechanisms, and prevention | |
Huang et al. | Poly (2-methacryloyloxyethyl phosphorylcholine) Grafted Bioprosthetic Heart Valve Exhibited Improved Antithrombogenicity and Anticalcification Properties | |
JP2022534228A (ja) | 石灰化沈着物の形成を防止し、生物学的マトリックス中の異種抗原を不活化するための方法 | |
Kong et al. | Immunogenicity assessment of swim bladder-derived biomaterials | |
Egerbacher et al. | Mammary Gland Secretory Concretions Contain Non‐Collagenous Bone Matrix Proteins | |
Meuris et al. | Antimineralization treatment | |
WO2013060103A1 (zh) | 一种处理动物源性胶原纤维材料的方法 | |
Noera et al. | Early alteration of bioprosthetic cardiac valves in sheep: influence of the immunological status | |
Du Plessis | Mitigation of the inflammatory response to bioprosthetic heart valve tissue through antigen-directed masking |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20180713 |
|
RD01 | Notification of change of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7426 Effective date: 20180713 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20191107 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200901 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201201 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210518 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210803 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211015 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220308 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20220607 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20220805 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20221004 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20221024 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7169645 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |